skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma

Review

(2853) Views  (827) Full article downloads

Authors: Francesca Cainelli, Alfredo Vallone

Published Date August 2009 Volume 2009:3 Pages 385 - 390
DOI: http://dx.doi.org/10.2147/BTT.S3915

Francesca Cainelli1, Alfredo Vallone2

1Department of Internal Medicine, School of Medicine, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana; 2Infectious Diseases Unit, Annunziata Hospital, Cosenza, Italy

Abstract: Kaposi’s sarcoma is a vascular tumor linked to the presence of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi’s sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries.

Keywords: pegylated liposomal doxorubicin, Kaposi’s sarcoma, HIV infection








Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Challenges in the management of juvenile idiopathic arthritis with etanercept
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Finding a new drug and vaccine for emerging swine flu: What is the concept?
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Palliative treatment of malignant ascites: profile of catumaxomab
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed